revyve
Commercial- Indications
- Diabetic foot ulcers, Leg ulcers, Pressure ulcers, Burns, Surgical wounds
Company intelligence / Profile preview
Kane Biotech has achieved commercial launch of multiple products in wound care and dermatology. Its DermaKB™ scalp care line demonstrated significant improvement in symptoms for users with severe scalp conditions in a large consumer trial. The company’s revyve™ antimicrobial wound gel has received FDA clearance. Additional pipeline programs are at various stages from pre-clinical to commercial development.[2][5]
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kane Biotech.